Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05070390 · ClinicalTrials.gov registry record · Phase 1
A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05070390 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 18 participants.
The verdict
NCT05070390, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study evaluated the safety, tolerability and pharmacokinetic (PK) effects of enlicitide chloride in participants with moderate renal impairment (RI) to those of healthy matched control participants. Moderate RI was defined as the estimated glomerular filtration rate (eGFR) ≥30 and \<60milliliter/minute/1.73meters\^2 (ml/min/1.73m\^2). There is no formal hypothesis.
Interventions
- DRUG Enlicitide Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2023-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05070390
The ClinicalTrials.gov registry entry for NCT05070390 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enlicitide Chloride is the first listed.
NCT05070390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05070390 about?
NCT05070390 is a clinical study titled "A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)". This study evaluated the safety, tolerability and pharmacokinetic (PK) effects of enlicitide chloride in participants with moderate renal impairment (RI) to those of healthy matched control participants. Moderate RI was defined as the estimated glomerular filtration rate (eGFR) ≥30 and \<60millilite...
What is the current status of trial NCT05070390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-11-16. Estimated completion is 2023-05-03.
What interventions are being tested in trial NCT05070390?
The interventions under investigation include: Enlicitide Chloride (DRUG).
Who is sponsoring clinical trial NCT05070390?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.